Discover 1,801 paid clinical trials in Greensboro, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,801
Active & ResponsiveNew
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
for
Ulcerative Colitis (UC), Crohn's Disease (CD),
Location: 1 recruiting location
Sponsor: University of North Carolina, Chapel Hill
Sex: All
Age: 18+
Code: NCT07237516
Recruiting
Active & ResponsiveNew
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
for
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Location: 10 recruiting locations
Sponsor: HealthTech Wound Care
Sex: All
Age: 18 - 70+
Code: NCT07172893
Recruiting
Active & Responsive
Inspiring Seniors Towards Exercise Promotion to Protect Cognition
for
Alzheimer Disease, Physical Activity
Location: 2 recruiting locations
Sponsor: Emory University
Sex: All
Age: 65+
Code: NCT06496425
Recruiting
Active & Responsive
Clinical Evaluation of WaveLight Plus LASIK
for
Myopia, Astigmatism
Location: 1 recruiting location
Sponsor: Laser Defined Vision
Sex: All
Age: 18+
Code: NCT07127757
Recruiting
Active & Responsive
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
for
Pulmonary Nodule, Solitary, Lung Cancer
Location: 21 recruiting locations
Sponsor: Veracyte, Inc.
Sex: All
Age: 29 - 70+
Code: NCT06426628
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
for
Intracranial Arteriosclerosis, Stroke
Location: 77 recruiting locations
Sponsor: University of Florida
Sex: All
Age: 30+
Code: NCT05047172
Phase3, Recruiting
Active & Responsive
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis